Released Nov 1, 2021, after the close
10-Q filed Nov 12, 2021, 43 days after period end · 0000950170-21-004267
Q3 2021 · 10-Q
Revenue—
Net Income-$5.98M-$5.98M N/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.10-$0.10 N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$5,854,000N/M
Operating Cash Flowderived-$3,457,000N/M
Free Cash Flowderived-$3,824,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|
| Net Income | -$5.98M | -$9.15M | -$8.55M |
| EPS Diluted | -$0.10 | -$0.18 | -$1.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR